Natco Pharma Share Price

Natco Pharma is a Hyderabad-based pharmaceutical company. Natco Pharma is a major manufacturer of branded oncology and Hepatitis C drugs in India. The company is well-known for producing affordable anti-cancer medicines.

Natco is into the production of finished dosage formulations, Active Pharmaceutical Ingredients (API) and crop health science products. The company, listed on both BSE and NSE, has expertise in the development, manufacturing and marketing of complex pharmaceuticals that focus on specific therapeutic areas. Natco specialises in catering to niche markets and offering solutions to address complex medical needs.

The company also provides contract manufacturing services.

Natco Pharma started its journey in 1981 with an initial investment of ₹33 lakh and 20 employees. It started the pharma division at Kothur, Mahaboobnagar, in Telangana. In 1986 it launched a parental manufacturing facility at Nagarjuna Sagar in Telangana. It launched the chemical division in 1993 and started the research division in Hyderabad in 1996. Natco launched the oncology division in 2003.

In a key development, Natco in 2012 received the compulsory licence from the Government of India for the patent-protected anti-cancer drug Nexavar of Bayer. The company launched the crop health sciences division in 2019.

Natco at present has eight manufacturing facilities, including six formulations facilities across India. The plants are equipped with modern research laboratories, capabilities in New Drug Development, etc. Natco currently has around 4500 employees.

Natco Pharma market capitalisation stood at over ₹15,500 crore as of January 30, 2024. Natco Pharma share price has surged more than 63% in the last three years.

Natco Pharma business operations

Natco Pharma markets and distributes products in more than 50 countries. It markets FDF products in the United States, India, Europe and the rest of the world.

Natco Pharma is primarily involved in the development, manufacturing and marketing of finished dosage formulations and active pharmaceutical ingredients. It has four main business segments— formulations, API manufacturing, contract manufacturing and crop health science division.

Formulations Segment

Natco focuses on niche therapeutic areas and complex products. Under its domestic formulations business, the company produces oncology products which include haemato-oncology and solid tumor products. It also produces speciality pharma catering to Orthopaedics and Gastroenterology. The orthopaedics range includes Bisphosphonates – the oral and injectable drugs. Under the gastroenterology division, it produces drugs for Chronic Hepatitis-B.

The company entered the Cardiology and Diabetology segment in 2017. The product range includes anti-hypertensives including Cilnidipine and its combinations (NATCOCIL & range). These are the first line of treatment of hypertension, Ivabradine (IVABRATCO) for stable angina and CHF.

The company’s international formulations business spans the US, Canada, Europe and Brazil. Sun-Ranbaxy, Alvogen, Aceto-Rising, Mylan, Teva, Lupin, Actavis, Breckenridge Pharmaceuticals and DRL are among the key partners of the company in the US market.

Active Pharmaceutical Ingredients

Natco has the expertise of over two decades in the development and commercialising niche APIs. It produces more than 50 APIs while Oncology remains its key therapeutic domain. API portfolio also includes Central Nervous System (CNS), pain management and CV care.

It has two API manufacturing facilities at Chennai and Makeguda that are approved by global health regulators such as USFDA, TGA, Hamburg Health Agency, PMDA, and KFDA.

Contract Manufacturing

Natco also provides contract manufacturing services to many leading pharmaceutical firms in India. Natco currently contract manufactures more than 40 products. These include Azacitidine, Bendamustine HCL, Bortezomib, Capecitabine and Desiferox.

Crop Health Sciences

Natco is looking to expand into the agrichemical space. Natco is focusing on a unique set of molecules for the Indian market, which has the potential to expand to other regions. It has formed strategic alliances with other pharma companies for making inroads into the segment. The activities have been initiated for both active ingredient and crop protection products.

Financial Highlights

• The company reported consolidated revenue of ₹2,811.7 crore in FY23, up 37.6% year-on-year compared to ₹2043.8 crore in FY22.
• Its profit after tax (PAT) increased multifold to ₹715.3 crore in FY23 as against ₹170 crore in FY22.
• The company’s earnings before interest, tax, depreciation and amortisation (EBITDA) surged to ₹1,040.2 crore in FY23 compared to ₹362.5 crore in FY22.
• The company’s earnings per share (EPS) stood at ₹39.18 in FY23 as against ₹9.32 in FY22.